NCT04047862: Study of BGB-A1217 in Combination With Tislelizumab in Advanced Solid Tumors

NCT04047862
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with active brain or leptomeningeal metastasis; Patients who received prior therapies targeting TIGIT
https://ClinicalTrials.gov/show/NCT04047862

Comments are closed.

Up ↑